Table 4.
Data concerning the pre-trial screening period of countries participating in the FAITH trial
| NL (N = 4) |
CA (N = 8) |
US (N = 14) |
P-value | |
|---|---|---|---|---|
| Screening period (days) | 55 (51 - 92) | 60 (56 - 74) | 50 (20 - 69) | 0.121 |
| Eligible patients (N) | 4 (3 - 6) | 4 (1 - 10) | 3 (1 - 6) | 0.571 |
| Total patients (N) | 6 (6 - 9) | 15 (15 - 34) | 6 (5 - 11) | 0.006a |
| Eligible patients (N per month) | 2.0 (1.7 - 2.4) | 1.5 (0.7 - 4.1) | 2.2 (1.1 - 5.0) | 0.786 |
| Total patients (N per month) | 3.3 (3.0 - 3.6) | 7.5 (5.6 - 17.4) | 5.0 (3.1 - 8.2) | 0.016 b |
| Proportion eligible patients (% of total) | 63 (53 - 67) | 14 (10 - 40) | 48 (29 - 71) | 0.062 |
NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites per country that data were available for.
Data are presented as median with P25-P75 given between brackets.
Statistics were calculated using the Kruskal-Wallis ANOVA.
Post-hoc pair wise comparisons were performed using Mann-Whitney U-test: a Statistical significance was reached when comparing NL vs. CA (p = 0.009), and CA vs. USA (p = 0.004), NL vs. USA: not significant. b Statistical significance was reached when comparing NL vs. CA (p = 0.007), other groups: not significant.